RxDoctor Payments Data

Jonathan Eskenazi, MD

Neurology · West Hollywood, CANPI 1568894988

Payments from drug & device makers

$174,942in general payments, 2019–2025

Across 1,631 payments — averaging $107.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$39K
  • AbbVie$34K
  • Amgen$29K
  • Teva Pharmaceuticals USA, Inc.$20K
  • Jazz Pharmaceuticals Inc.$10K
  • Sanofi$8K
  • plus $34K from 54 others

What the payments were for

  • Consulting fees$1,9002%
  • Speaking & faculty fees$49,54050%
  • Travel & lodging$1,6132%
  • Food & beverage$46,54147%
  • Education$1150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.8$39,353
AbbVie(2 entities)225$33,895
Amgen(2 entities)89$29,424
Teva Pharmaceuticals USA, Inc.108$19,597
Jazz Pharmaceuticals Inc.13$9,795
Sanofi20$8,349
SK Life Science, Inc.73$2,521
Neurocrine Biosciences, Inc.85$2,443
UCB, Inc.73$2,356
Lilly USA, LLC67$1,764
Bristol Myers Squibb66$1,672
Novartis54$1,627
AstraZeneca49$1,496
Livanova USA, Inc.48$1,421
Genentech USA, Inc.37$1,125
Mallinckrodt Hospital Products Inc.41$1,044
Catalyst Pharmaceuticals, Inc.28$996
Noctrix Health, Inc.9$941
Biogen22$917
Argenx US, Inc.12$911
MDD US Operations, LLC37$850
Harmony Biosciences LLC23$773
Otsuka America Pharmaceutical, Inc.26$764
Avanir Pharmaceuticals, Inc.36$717
Tonix Medicines, Inc.26$710
Neurelis, Inc.21$692
Vanda Pharmaceuticals Inc.18$623
CSL Behring25$618
Eisai Inc.15$541
Sumitomo Pharma America, Inc.20$475
Forte Bio-pharma LLC22$473
Scilex Pharmaceuticals Inc.19$386
Abbott21$372
Almatica Pharma LLC16$365
Amneal Pharmaceuticals LLC7$304
Medtronic(2 entities)9$300
Octapharma USA, Inc.10$295
ANI Pharmaceuticals, Inc.10$285
Impel Pharmaceuticals Inc.9$268
E.r. Squibb & Sons, L.L.C.10$250
Supernus Pharmaceuticals, Inc.14$246
Johnson & Johnson(2 entities)4$239
Tanabe Pharma America, Inc.9$238
GE HealthCare9$230
Acadia Pharmaceuticals Inc9$229
Axsome Therapeutics, Inc.8$217
Idorsia Pharmaceuticals US Inc10$207
Pfizer7$193
Kyowa Kirin, Inc.8$184
Nevro Corp.1$125
Lundbeck LLC5$111
EMD Serono, Inc.4$103
Mylan Specialty L.p.1$100
Sunovion Pharmaceuticals Inc.4$99
Life Molecular Imaging Ltd4$91
OWP Pharmaceuticals, Inc.3$69
Arbor Pharmaceuticals, Inc.3$57
Ipsen Biopharmaceuticals, Inc2$56
Cycle Pharmaceuticals Inc2$56
Merz North America, Inc.2$50

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$174,942 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$3,177,889
Medicare patients
1,816
Services billed
18,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-50363$8,679,181
OctagamImmun Globg(Igg)/Malt/Iga Ov50108$2,581,520
Gamunex-CImmune Globul G/Gly/Iga Avg 46104$1,884,696
PanzygaImmun Glob G(Igg)-Ifas/Glycine28$957,119
NamzaricMemantine Hcl/Donepezil Hcl355$222,727
UbrelvyUbrogepant216$219,929
Emgality PenGalcanezumab-Gnlm215$175,120
IngrezzaValbenazine Tosylate21$167,774
Nurtec OdtRimegepant Sulfate95$89,851
QuliptaAtogepant75$79,560
BriviactBrivaracetam50$73,664
CopaxoneGlatiramer Acetate12$70,004
AptiomEslicarbazepine Acetate47$64,402
HorizantGabapentin Enacarbil92$55,585
Lidocaine855$52,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$618$8,679,181363 claims
PfizerOctagam, Panzyga, Nurtec Odt$193$3,628,489231 claims
AbbVieNamzaric, Ubrelvy, Qulipta$33,895$522,216646 claims
Neurocrine Biosciences, Inc.Ingrezza$2,443$167,77421 claims
UCB, Inc.Briviact, Neupro$2,356$88,82468 claims
Teva Pharmaceuticals USA, Inc.Copaxone$19,597$70,00412 claims
Sunovion Pharmaceuticals Inc.Aptiom$99$64,40247 claims
Arbor Pharmaceuticals, Inc.Horizant$57$55,58592 claims
SK Life Science, Inc.Xcopri$2,521$34,56136 claims
Scilex Pharmaceuticals Inc.Ztlido$386$31,57882 claims
Avanir Pharmaceuticals, Inc.Nuedexta$717$19,85718 claims
Neurelis, Inc.Valtoco$692$14,18211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in West Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →